Zane Cohen Centre for Digestive Diseases, Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, Ontario, Canada.
Division of Gastroenterology, Mount Sinai Hospital, Sinai Health System, University of Toronto, Toronto, Ontario, Canada.
J Crohns Colitis. 2022 Jul 14;16(6):900-910. doi: 10.1093/ecco-jcc/jjab186.
Crohn's disease [CD] recurrence following ileocolic resection [ICR] is common. We sought to identify blood-based biomarkers associated with CD recurrence.
CD patients undergoing ICR were recruited across six centres. Serum samples were obtained at post-operative colonoscopy. A multiplex immunoassay was used to analyse 92 inflammation-related proteins [Olink Proteomics]. Bayesian analysis was used to identify proteins associated with increasing Rutgeerts score. Identified proteins were used in receiver operating characteristic [ROC] analysis to examine the ability to identify CD recurrence [Rutgeerts score ≥i2]. Existing single cell data were interrogated to further elucidate the role of the identified proteins.
Data from 276 colonoscopies in 213 patients were available. Median time from surgery to first and second colonoscopy was 7 (interquartile range [IQR] 6-9) and 19 [IQR 16-23] months, respectively. Disease recurrence was evident at 60 [30%] first and 36 [49%] second colonoscopies. Of 14 proteins significantly associated with Rutgeerts score, the strongest signal was seen for CXCL9 and MMP1. Among patients on anti-tumour necrosis factor drugs, CXCL9 and CXCL11 were most strongly associated with Rutgeerts score. Both are CXCR3 ligands. Incorporation of identified proteins into ROC analysis improved the ability to identify disease recurrence as compared to C-reactive protein alone: area under the curve [AUC] 0.75 (95% confidence interval [CI]: 0.66-0.82] vs 0.64 [95% CI 0.56-0.72], p = 0.012. Single cell transcriptomic data provide evidence that innate immune cells are the primary source of the identified proteins.
CXCR3 ligands are associated with CD recurrence following ICR. Incorporation of novel blood-based candidate biomarkers may aid in identification of CD recurrence.
回肠结肠切除术(ICR)后克罗恩病(CD)的复发很常见。我们试图确定与 CD 复发相关的基于血液的生物标志物。
在六个中心招募接受 ICR 的 CD 患者。在术后结肠镜检查时采集血清样本。使用多重免疫测定法分析 92 种炎症相关蛋白(Olink 蛋白质组学)。贝叶斯分析用于识别与 Rutgeerts 评分增加相关的蛋白。鉴定的蛋白用于接收者操作特征(ROC)分析,以检查识别 CD 复发(Rutgeerts 评分≥i2)的能力。检查现有单细胞数据以进一步阐明鉴定蛋白的作用。
213 名患者的 276 次结肠镜检查数据可用。从手术到第一次和第二次结肠镜检查的中位时间分别为 7(四分位距 [IQR] 6-9)和 19 [IQR 16-23] 个月。在 60 次[30%]第一次和 36 次[49%]第二次结肠镜检查中明显出现疾病复发。在与 Rutgeerts 评分显著相关的 14 种蛋白中,CXCL9 和 MMP1 的信号最强。在接受抗肿瘤坏死因子药物治疗的患者中,CXCL9 和 CXCL11 与 Rutgeerts 评分最相关。两者均为 CXCR3 配体。与单独使用 C 反应蛋白相比,将鉴定的蛋白纳入 ROC 分析可提高识别疾病复发的能力:曲线下面积 [AUC] 为 0.75(95%置信区间 [CI]:0.66-0.82)与 0.64(95%CI 0.56-0.72)相比,p=0.012。单细胞转录组数据提供了证据表明固有免疫细胞是鉴定蛋白的主要来源。
CXCR3 配体与 ICR 后 CD 的复发有关。新型基于血液的候选生物标志物的纳入可能有助于识别 CD 的复发。